BCL2 and metabolic dysfunction-associated steatotic liver disease: In a previous study, we discovered that acridone derivative A22 could up-regulate the transcription and translation of BCL-2 by binding to and stabilizing BCL-2 promoter i-motif structure, which could alleviate the hepatic apoptosis-associated pathological features of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in mouse models [28].